title: Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study.
abstract: OBJECTIVE
  Palonosetron is a novel 5-hydroxytryptamine(3) (5 HT(3)) receptor antagonist, which has been shown to be superior to first generation 5 HT(3) receptor antagonists regarding the prevention of acute, delayed and overall chemotherapy-induced nausea and vomiting. First generation 5 HT(3) receptor antagonists may induce electrocardiographic changes of heart rate and repolarization. The acute cardiac effect of palonosteron is unknown. The purpose of this study is to determine acute effects of palonosetron on electrocardiographic (ECG) parameters in cancer patients.
  
  
  METHODS
  The study had a prospective design. Seventy-six cancer patients with normal cardiac function who received palonosetron for prevention of chemotherapy-induced nausea and vomiting were enrolled. Standard 12-lead ECG recordings were performed at baseline and 30 min after palonosetron administration. P wave durations and corrected QT intervals were measured; P wave dispersion (Pd) and QTc dispersion were calculated.
  
  
  RESULTS
  Median heart rate did not differ among 76 patients enrolled before and after palonosetron administration (p: 0.6). Systolic and diastolic blood pressures were not significantly different before and after palonosteron (p values 0.9 and 0.3, respectively). Although median QT min value was higher after palonosetron administration than before palonosetron administration, the difference was not statistically significant (p: 0.6).
  
  
  CONCLUSIONS
  Palonosetron seems to have no acute arrhythmogenic potential.
authors.affiliation: Department of Radiation Oncology, Konya Training and Research Hospital, Konya, Turkey. drcagdasyavas@gmail.com
authors.forename: C
authors.initials: C
authors.lastname: Yavas
authors.forename: U
authors.initials: U
authors.lastname: Dogan
authors.forename: G
authors.initials: G
authors.lastname: Yavas
authors.forename: M
authors.initials: M
authors.lastname: Araz
authors.forename: O Yavas
authors.initials: OY
authors.lastname: Ata
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects; D004562:Electrocardiography / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D007546:Isoquinolines / Q000494:pharmacology*; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control; D009369:Neoplasms / Q000188:drug therapy; D000077924:Palonosetron; D011446:Prospective Studies; D011812:Quinuclidines / Q000494:pharmacology*; D012702:Serotonin Antagonists / Q000494:pharmacology*; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D007546:Isoquinolines; D011812:Quinuclidines; D012702:Serotonin Antagonists; D000077924:Palonosetron